# The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients

> **NCT05289986** · PHASE4 · TERMINATED · sponsor: **Chelsea and Westminster NHS Foundation Trust** · enrollment: 18 (actual)

## Conditions studied

- Hiv

## Interventions

- **DRUG:** DELSTRIGO 100Mg-300Mg-300Mg Tablet

## Key facts

- **NCT ID:** NCT05289986
- **Lead sponsor:** Chelsea and Westminster NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-21
- **Primary completion:** 2024-11-21
- **Final completion:** 2024-11-21
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The CI, sponsor and funder jointly made the decision to end the trial due to lack of recruitment, as well as due to delays it was felt value of the primary endpoint had lessened to a point where its scientific value was questioned.
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289986, "The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05289986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*